777 IS ADJUVANT CHEMOTHERAPY FOR ESOPHAGEAL CANCER WITH RESIDUAL DISEASE AFTER TRIMODALITY THERAPY FUTILE? A NATIONWIDE MULTICENTRIC SURVEY

Résumé fourni par la source

Abstract For patients with resectable locally advanced esophageal cancer (EC), trimodality therapy associating neoadjuvant chemoradiation and surgery is the standard of care. However, the risk of recurrence for patients with residual disease (RD) remains high and there is no established adjuvant treatment modality in this setting. Adjuvant immunotherapy recently exhibited promising results but ACT could also play a beneficial role. This study evaluated the potential benefit of ACT in RD after trimodality therapy for EC. Methods A multicenter database for the surgical treatment of EC collected data from 30 university hospitals (2000–2010). Patients with RD in completely resected EC after trimodality therapy where included and separated in an ACT group and a non-ACT group. Demographics, tumor and treatment characteristics, morbidity, overall and recurrence-free survival (OS and RFS) where compared. Uni and multivariate analysis were performed to identify factors associated with OS. Survival analysis of patients treated with and without ACT was performed in a propensity score matched study. Results From 2944 patients included, 484 had RD after trimodality therapy, and 9.3% (n = 45) were treated with ACT. There were no major differences in demographics, preoperative tumor and treatment characteristics between groups. Major complications where higher in the non-ACT group (31 vs 20%, p = 0.018). ACT group had more nodal involvement (78 vs 45%, p < 0.001). OS and RFS were significantly worse in the ACT group (median: 36.0 vs 46.7mo, p < 0.001 and 25.5 vs 47.9mo, p = 0.029 respectively). After multivariate analysis, ACT was independently associated with worse OS (HR = 3.69, p < 0.001). In the propensity matched study, OS and RFS remained worse in ACT group. Conclusion This study supports current recommendations concerning ACT abstention in EC with RD after trimodality therapy. In light of the promising results of the BMS Checkmate 577 study, adjuvant immunotherapy in this setting should therefore be considered as the first choice of treatment.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.